骨髓增生性疾病所致门静脉海绵样变性1例报告

韩冰; 涂传涛

doi:10.3969/j.issn.1001-5256.2023.06.025

骨髓增生性疾病所致门静脉海绵样变性1例报告

DOI: 10.3969/j.issn.1001-5256.2023.06.025

韩冰,
涂传涛^, ,

同济大学附属上海市第四人民医院消化内科，上海 200434

基金项目:

国家自然科学基金 (81970531);

上海市虹口区卫生健康委员会面上项目 (2002-16)

伦理学声明：本例报告已获得患者/患者家属知情同意。

利益冲突声明：本文不存在任何利益冲突。

作者贡献声明：韩冰负责课题设计，资料分析，撰写论文；涂传涛负责拟定写作思路，收集资料，指导撰写文章并最后定稿。

详细信息

通信作者:
TU Chuantao, tuchuantao@hotmail.com(ORCID: 0000-0002-9106-9868)

计量
- 文章访问数: 341
- HTML全文浏览量: 92
- PDF下载量: 28
- 被引次数: 0
出版历程
- 收稿日期: 2022-10-20
- 录用日期: 2022-11-27
- 出版日期: 2023-06-20

Cavernous transformation of the portal vein caused by myeloproliferative disease: A case report

Bing HAN,
Chuantao TU^{,
,}

Department of Gastroenterology, Shanghai Fourth People's hospital, Tongji University School of Medicine, Shanghai 200434, China

Research funding:

National Natural Science Foundation of China (81970531);

General Project of Shanghai Hongkou District Health Commission (2002-16)

摘要

- 骨髓增殖性疾病 /
- 门静脉海绵样变性 /
- 食管和胃静脉曲张
- Myeloproliferative Disorders /
- Cavernous Transformation of Portal Vein /
- Esophageal and Gastric Varices

HTML全文

图 1 胃镜结果

注：a，食管数条纵行静脉曲张充盈；b，胃底静脉曲张球伴表面糜烂。

Figure 1. Gastroscopic results

下载: 全尺寸图片幻灯片

图 2 门静脉增强CT结果

注：a，门静脉海绵样变性；b，腹腔多发分支血管扭曲，脾肿大。

Figure 2. Portal vein enhanced CT results

下载: 全尺寸图片幻灯片

图 3 骨髓穿刺Wright-Giemsa染色结果

注：a，骨髓增生活跃，巨核系多见，部分胞浆丰富，体积巨大(×100)；b，巨核细胞胞浆丰富、体积巨大(×400)；c，巨核细胞胞浆丰富、体积巨大，可见局部区域血小板形成(×1 000)；d，巨核细胞胞浆丰富、体积巨大且核分叶较多(×400)；e，巨核细胞胞浆丰富、体积巨大且核分叶较多，可见边缘血小板形成(×1 000)。

Figure 3. Bone marrow puncture results

下载: 全尺寸图片幻灯片

参考文献(12)

[1]	CUNNINGHAM ME, PARASTANDEH-CHEHR G, CEROCCHI O, et al. Noninvasive predictors of high-risk varices in patients with non-cirrhotic portal hypertension[J]. Can J Gastroenterol Hepatol, 2019, 2019: 1808797. DOI: 10.1155/2019/1808797.
[2]	KHANNA R, SARIN SK. Non-cirrhotic portal hypertension-diagnosis and management[J]. J Hepatol, 2014, 60(2): 421-441. DOI: 10.1016/j.jhep.2013.08.013.
[3]	SIRAMOLPIWAT S, SEIJO S, MIQUEL R, et al. Idiopathic portal hypertension: natural history and long-term outcome[J]. Hepatology, 2014, 59(6): 2276-2285. DOI: 10.1002/hep.26904.
[4]	ZHANG BJ, HAN GH, FAN DM. Research advances in non-cirrhotic portal hypertension[J]. J Clin Hepatol, 2016, 32(2): 245-249. DOI: 10.3969/j.issn.1001-5256.2016.02.009. 张博静, 韩国宏, 樊代明. 非肝硬化性门静脉高压症的研究现状[J]. 临床肝胆病杂志, 2016, 32(2): 245-249. DOI: 10.3969/j.issn.1001-5256.2016.02.009.
[5]	de FRANCHIS R. Expanding consensus in portal hypertension: report of the Baveno Ⅵ Consensus Workshop: stratifying risk and individualizing care for portal hypertension[J]. J Hepatol, 2015, 63(3): 743-752. DOI: 10.1016/j.jhep.2015.05.022.
[6]	DELEVE LD, VALLA DC, GARCIA-TSAO G, et al. Vascular disorders of the liver[J]. Hepatology, 2009, 49(5): 1729-1764. DOI: 10.1002/hep.22772.
[7]	LI H, SUN PM, SUN HW, et al. Progress in clinical diagnosis and treatment of cavernous transformation of the portal vein[J]. World Chin J Dig, 2021, 29(12): 662-669. DOI: 10.11569/wcjd.v29.i12.662j. 李昊, 孙培鸣, 孙宏伟, 等. 门静脉海绵样变性的临床诊疗进展[J]. 世界华人消化杂志, 2021, 29(12): 662-669. DOI: 10.11569/wcjd.v29.i12.662j.
[8]	RUNGJIRAJITTRANON T, OWATTANAPANICH W, UNGPRASERT P, et al. A systematic review and meta-analysis of the prevalence of thrombosis and bleeding at diagnosis of Philadelphia-negative myeloproliferative neoplasms[J]. BMC Cancer, 2019, 19(1): 184. DOI: 10.1186/s12885-019-5387-9.
[9]	LEVINE RL, WADLEIGH M, COOLS J, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis[J]. Cancer Cell, 2005, 7(4): 387-397. DOI: 10.1016/j.ccr.2005.03.023.
[10]	MCCLURE R, MAI M, LASHO T. Validation of two clinically useful assays for evaluation of JAK2V617F mutation in chronic myeloproliferative disorders[J]. Leukemia, 2006, 20(1): 168-171. DOI: 10.1038/sj.leu.2404007.
[11]	SUN CC, LI Y, TIAN WJ, et al. JAK2V617F mutation and TNF-α expression in myeloproliferative neoplasms and their correlation[J]. J Exp Hematol, 2014, 22(4): 1022-1026. DOI: 10.7534/j.issn.1009-2137.2014.04.025. 孙聪聪, 李英, 田文君, 等. 骨髓增殖性肿瘤中JAK2V617F突变和TNF-α的表达及两者的相关性研究[J]. 中国实验血液学杂志, 2014, 22(4): 1022-1026. DOI: 10.7534/j.issn.1009-2137.2014.04.025.
[12]	TEFFERI A. Primary myelofibrosis: 2019 update on diagnosis, risk-stratification and management[J]. Am J Hematol, 2018, 93(12): 1551-1560. DOI: 10.1002/ajh.25230.